---
title: "Celcuity plunges nearly 17% as breast cancer drug launch delayed"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292779112.md"
description: "Celcuity plunged 17% to $92.68. HC Wainwright raised price target to $155, but breast cancer drug delay dragged shares."
datetime: "2026-07-15T13:52:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292779112.md)
  - [en](https://longbridge.com/en/news/292779112.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292779112.md)
generator: "portal-rs"
---

# Celcuity plunges nearly 17% as breast cancer drug launch delayed

Celcuity(CELC.US) 盘中跌**16.54%**，现报**92.68**美元。

消息面上，HC Wainwright 将 Celcuity 目标价上调至 155 美元。然而， Reuters 报道称 Celcuity 乳腺癌药物发布延迟，影响了其首个 FDA 批准的利好效应，对股价形成拖累。

### Related Stocks

- [CELC.US](https://longbridge.com/en/quote/CELC.US.md)

## Related News & Research

- [Celcuity (CELC) Could Be 40% Undervalued After REVTORPYK FDA Filing](https://longbridge.com/en/news/297884483.md)
- [Celcuity (CELC) Losses Widen As Investors Ask If The Bull Case Still Supports Valuation](https://longbridge.com/en/news/296708642.md)
- [Celcuity Analysts Slash Their Forecasts After Q2 Loss](https://longbridge.com/en/news/295935858.md)
- [Celcuity submits FDA sNDA for REVTORPYK in PIK3CA-mutant advanced breast cancer](https://longbridge.com/en/news/297045627.md)
- [Celcuity Reports Q2 2026 Results: Full Earnings Call Transcript](https://longbridge.com/en/news/295849905.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**